Rivaroxaban (Xarelto; Bayer/Janssen) is a reasonable alternative to warfarin for patients with atrial fibrillation/flutter and a bioprosthetic mitral valve, the randomized RIVER trial indicates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results